Last $1.51 USD
Change Today -0.02 / -1.31%
Volume 141.9K
BIOD On Other Exchanges
Symbol
Exchange
BIOD is not on other exchanges.
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

biodel inc (BIOD) Snapshot

Open
$1.51
Previous Close
$1.53
Day High
$1.53
Day Low
$1.50
52 Week High
03/6/14 - $3.71
52 Week Low
10/14/14 - $1.20
Market Cap
35.4M
Average Volume 10 Days
205.0K
EPS TTM
$-0.66
Shares Outstanding
23.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIODEL INC (BIOD)

Related News

No related news articles were found.

biodel inc (BIOD) Related Businessweek News

No Related Businessweek News Found

biodel inc (BIOD) Details

Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company is conducting a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-123, which has been evaluated in a Phase 2 clinical trial combining recombinant human insulin with its proprietary combination of excipients; and BIOD-531, a concentrated ultra-rapid-acting insulin formulation. The company was founded in 2003 and is headquartered in Danbury, Connecticut.

30 Employees
Last Reported Date: 12/19/14
Founded in 2003

biodel inc (BIOD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $688.4K
Chief Medical Officer
Total Annual Compensation: $437.0K
Chief Compliance Officer, General Counsel and...
Total Annual Compensation: $334.2K
Compensation as of Fiscal Year 2014.

biodel inc (BIOD) Key Developments

Biodel Inc. - Special Call

To discuss the positive preliminary results from Study 3-151, a Phase 2a clinical trial

Biodel Inc. Announces Positive Preliminary Results from Study 3-151

Biodel Inc. announced positive preliminary results from Study 3-151, a Phase 2a clinical trial comparing Biodel’s proprietary, concentrated insulin formulation BIOD-531 to Humalog Mix 75/25 and Humulin R U-500 in patients with type 1 and type 2 diabetes with severe insulin resistance who use at least 150 units of insulin per day or at least 100 units of insulin in a single injection. Many type 2, and some type 1, diabetes patients in clinical practice are treated with pre-mixed insulins, such as Humalog Mix 75/25, in order to receive both basal and prandial insulin in single injections. Pre-mixed insulin is commonly dosed before breakfast and before dinner and is usually used in patients who are not candidates for an intensive basal-bolus insulin regimen which often requires four or more injections per day. Humulin R U-500 is used most commonly to treat type 2 diabetes patients with severe insulin resistance who require very high doses of insulin—typically greater than 150 units per day. Humulin R U-500 is currently the only concentrated insulin available in the U.S. BIOD-531 is an ultra-rapid-acting formulation of recombinant human insulin (RHI) at a concentration of 400 units/ml (U-400) combined with EDTA, citrate and magnesium sulfate. In the Phase 1 Study 3-150, the results of which were released in February 2014, BIOD-531 administered to non-diabetic, obese volunteers demonstrated ultra-rapid absorption and onset of action compared to Humalog Mix 75/25 and Humulin R U-500, and had an extended duration of action expected to be suitable for basal insulin needs. The Phase 2a Study 3-152, which completed in August 2014, demonstrated that a single dose of BIOD-531 conferred better postprandial glucose control for two consecutive meals compared to Humalog Mix 75/25 or Humulin R U-500 when administered to type 2 diabetes patients with moderate insulin resistance (insulin dose requirement between 50-150 units/day). Postprandial glucose control with BIOD-531 dosed after the standardized meal was also superior to the control provided by the comparators dosed prior to the standardized meal. The results of this recently completed Phase 2a Study 3-151 demonstrate that BIOD-531 may confer similar clinically meaningful benefits of superior mealtime coverage and adequate basal duration for diabetes patients with higher degrees of insulin resistance and insulin dose requirements.

Biodel Inc. Reports Consolidated Financial Results for the Fourth Quarter and Year Ended September 30, 2014

Biodel Inc. reported consolidated financial results for the fourth quarter and year ended September 30, 2014. For the quarter, the company reported a net loss of $2.3 million or $0.10 per basic and diluted share compared to a net loss of $0.8 million or $0.04 per basic and diluted share, for the quarter ended September 30, 2013. For the year, the company reported a net loss of $14.1 million, or $0.66 per basic and diluted share compared to a net loss of $19.3 million, or $1.24 per basic and diluted share, for the year ended September 30, 2013. Loss before tax provision was $14.10 million compared to $19.32 million reported a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOD:US $1.51 USD -0.02

BIOD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOD.
View Industry Companies
 

Industry Analysis

BIOD

Industry Average

Valuation BIOD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODEL INC, please visit www.biodel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.